Clinical trialNCT06847867RecruitingPhase 2Interventional

A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome

SponsorGlaxoSmithKlineEnrollment80Myelodysplastic Syndromes

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

39 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Gsk Investigational Site
Calgary, Alberta, Canada
Michelle Geddes
Recruiting
Gsk Investigational Site
Toronto, Ontario, Canada
Karen Yee
Recruiting

France

Gsk Investigational Site
Le Mans, France
Kamel Laribi
Recruiting
Gsk Investigational Site
Nice, France
Thomas Cluzeau
Recruiting
Gsk Investigational Site
Paris, France
Pierre Fenaux
Recruiting
Gsk Investigational Site
Poitiers, France
Jose Torregrosa Diaz
Recruiting
Gsk Investigational Site
Toulouse, France
Thibault Comont
Recruiting

Germany

Gsk Investigational Site
Münster, North Rhine-Westphalia, Germany
Jan-Henrik Mikesch
Recruiting
Gsk Investigational Site
Dresden, Germany
Ekaterina Balaian
Recruiting
Gsk Investigational Site
Leipzig, Germany
Madlen Jentzsch
Recruiting

Italy

Gsk Investigational Site
Udine, Friuli Venezia Giulia, Italy
Mario Tiribelli
Recruiting
Gsk Investigational Site
Catania, Italy
Giuseppe Palumbo
Recruiting
Gsk Investigational Site
Florence, Italy
Valeria Santini
Recruiting
Gsk Investigational Site
Milan, Italy
Bruno Fattizzo
Recruiting
Gsk Investigational Site
Orbassano to, Italy
Marco Gobbi
Recruiting
Gsk Investigational Site
Rozzano MI, Italy
Matteo Della Porta
Recruiting

Poland

Gsk Investigational Site
Chorzów, Silesian Voivodeship, Poland
Sebastian Grosicki
Recruiting
Gsk Investigational Site
Warsaw, Poland
Krzysztof Madry
Recruiting

South Korea

Gsk Investigational Site
Seongnam-si Gyeonggi-do, South Korea
Soo-Mee Bang
Recruiting
Gsk Investigational Site
Seoul, South Korea
Yoo-Jin Kim
Recruiting
Gsk Investigational Site
Seoul, South Korea
JunShik Hong
Recruiting
Gsk Investigational Site
Seoul, South Korea
JeHwan Lee
Recruiting

Spain

Gsk Investigational Site
Barcelona, Spain
Montserrat Arnan
Recruiting
Gsk Investigational Site
Barcelona, Spain
David Valcarcel Ferreiras
Recruiting
Gsk Investigational Site
Madrid, Spain
Ana Alfonso Pierola
Recruiting
Gsk Investigational Site
Málaga, Spain
Regina Garcia Delgado
Recruiting
Gsk Investigational Site
Ourense, Spain
José Luis Sastre Moral
Recruiting
Gsk Investigational Site
PamplonaNavarra, Spain
Ana Alfonso Pierola
Recruiting
Gsk Investigational Site
Salamanca, Spain
María Díez Campelo
Recruiting
Gsk Investigational Site
Valencia, Spain
María del Mar Tormo Díaz
Recruiting

United Kingdom

Gsk Investigational Site
Boston, United Kingdom
Ciro Rinaldi
Recruiting
Gsk Investigational Site
London, United Kingdom
Austin Kulasekararaj
Recruiting
Gsk Investigational Site
Manchester, United Kingdom
Daniel Wiseman
Recruiting

United States

Gsk Investigational Site
Goodyear, Arizona, United States
Zawit Misam
Recruiting
Gsk Investigational Site
Duarte, California, United States
Brian Ball
Recruiting
Gsk Investigational Site
Irvine, California, United States
Brian Ball
Recruiting
Gsk Investigational Site
New Haven, Connecticut, United States
Amer Zeidan
Recruiting
Gsk Investigational Site
Canton, Ohio, United States
Nashat Gabrail
Recruiting
Gsk Investigational Site
Houston, Texas, United States
Guillermo Garcia-Manero
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 5 Jun 2025
Primary completion: 14 Jul 2027
Completion: 29 Dec 2027
Last update posted: 2 Jun 2026
Registered enrollment: 80
Registry id: NCT06847867

Cross-registrations

EU-CTR / CTIS (EudraCT)2024-519928-24

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.